The World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease

The following text was composed for marketing materials for the 10th WCIRDC in November, 2012.

The World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) is a unique and exciting multidisciplinary program, to be held this year in Los Angeles, California. The Congress is the premiere global meeting dedicated to obesity, diabetes, metabolism and energy balance, linking research to clinical practice, and highlighting our theme — exploring new frontiers in metabolism — tomorrow’s clinical science today.

Since its inception, the Congress has become a home to clinical and basic scientists, researchers and practicing clinicians. The distinguished global faculty, combined with the Congress’ unique bench-to-bedside approach, has culminated in a state-of-the-art program. The expert and creative faculty promotes a new understanding of metabolic diseases; facilitates the development of future therapeutic modalities; and has been the cornerstone of the success of the Congress.

In recent years, there has evolved significant awareness of the contribution of multiple systems to energy metabolism, obesity, diabetes, and cardiovascular disease (CVD); notably incretins, gut hormones, and the brain. Dr. Gerald Reaven’s pioneering work crystallized the relationship of insulin resistance to these conditions, and various cancers. Of particular interest is the complicated interrelationship of nutrients, the gut, fat cell, insulin, leptin, and their respective resistance states, along with circadian rhythm, sleep disturbances, and the neuroendocrine system. The WCIRDC has become a distinguished platform where the interaction of these multiple metabolic systems is evaluated in a clinical, multidisciplinary environment. Ultimately the Congress focuses on innovative approaches to developing a comprehensive plan for managing risk factors and diseases, which include lifestyle and medications.

This year will introduce new aspects of bone, fat, leptin and adiponectin, as well as mitochondria and related proteins, to metabolic impairment in human disease.

New this year – all sessions will be followed by a panel discussion, and a clinical implications commentary by recognized experts. The Congress will conclude with a special symposium, “Diabetes and the Heart.” The 10th WCIRDC welcomes the annual meeting of the American Heart Association (AHA) to Los Angeles, which begins as our Congress ends.

WCIRDC Program Objectives

The program is designed to evaluate both clinical and basic science aspects of obesity, diabetes, and CVD, focusing on insulin resistance, hyperinsulinemia, fat cell, adipokines, the gut, the brain, and energy metabolism. The goal is to understand pathophysiology, and develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

  • Understand the comprehensive approach to the treatment of obesity, hypertension, and dyslipidemia and the prevention of CVD, including nutrition management.
  • Explain the role of IR and hyperinsulinemia in CVD, liver disease, PCOS, congestive heart failure (CHF), and the development of certain cancers.
  • Understand the potential role of the peroxisome proliferator-activated receptors (PPAR) in lipid abnormalities, the endothelium, and vascular pathology.
  • Discuss the role of the mitochondria and their related proteins, in particular humanin, in metabolic abnormalities, aging, and the development of plaques and atherosclerosis.
  • Understand the interaction between fat, bone, and glucose, and its potential relationship to IR and diabetes.
  • Understand the sortillin pathway as a target for reducing low-density lipoprotein (LDL) and CVD risk.
  • Recognize the role of the hyperstimulated beta-cell in obese adolescents, as a prelude to diabetes.
  • Be aware of calcium scoring as a predictor and potential follow-up of CVD in cardiometabolic syndrome and diabetes.
  • Describe the impact of chronic kidney disease (CKD) on cardiometabolic risk and CVD.
  • Understand the role of the gut-brain dopamine axis, taste and visual stimulus in Reward Deficiency Syndrome (RDS), leading to overeating and obesity.
  • Relate the potential relationship of IR to circadian rhythm, sleep disorders, the brain, incretin hormones and metabolic disorders.
  • Educate the participants about the effects of incretins on diabetes, obesity and effects beyond glucose homeostasis.

TARGET AUDIENCE: This course is designed for endocrinologists, cardiologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dieticians, nurses, registered nurses, and any health care professional who is interested in insulin resistance and the interaction of multiple metabolic mechanisms, and the effect on health and society, as well as in potential treatment and prevention.